|
MedImmune llc
cd39 antagonist  Cd39 Antagonist, supplied by MedImmune llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/cd39+antagonist/pmc09979453-3-5-2?v=MedImmune+llc Average 90 stars, based on 1 article reviews
cd39 antagonist - by Bioz Stars,
2026-07
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Molecular Cancer
Article Title: CD39/CD73/A2AR pathway and cancer immunotherapy
doi: 10.1186/s12943-023-01733-x
Figure Lengend Snippet: The two ectonucleotidases CD39 and CD73 control the metabolic fate of ATP and adenosine in the extracellular environment. Extracellular ATP is converted into its metabolites ADP and AMP sequentially by CD39, which is then further metabolized to adenosine by CD73. Activated CD39/CD73/A2AR signaling within the TME will suppress the function of antitumor immune cells (T cells, B cells, NK cells, and DCs) but promote the activity of the regulatory immune cells (MDSCs and Tregs), thus giving rise to a immunosuppressive TME. Notes: TME: tumor microenvironment; NK: natural killer; DCs: dendritic cells; MDSC: myeloid-derived suppressor cells; Treg: regulatory T cells; Th17: T helper 17 cells
Article Snippet: IPH5201 ,
Techniques: Control, Activity Assay, Derivative Assay
Journal: Molecular Cancer
Article Title: CD39/CD73/A2AR pathway and cancer immunotherapy
doi: 10.1186/s12943-023-01733-x
Figure Lengend Snippet: Gene-expression landscape of the three major components (CD39, CD73 and A2AR) in the adenosine signaling pathway in various solid cancer types. The Cancer Genome Altas (TCGA) analysis RNA-sequencing (RNA-seq) data of ENTPD1( A ), NT5E ( B ) and ADORA2A ( C ), encoding the proteins CD39, CD73, A2AR, respectively, in human cancers. Notes: LUAD: lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; PRAD: Prostate; HNSC: Head and Neck squamous cell; KIRC: Kidney renal clear cell carcinoma; UCEC: Uterinecorps Endometrial carcinoma; PCPG: Pheochromocytoma; LIHC: Liver hepatocellular carcinoma; COAD: Colon adenocarcinoma; READ: Rectum adenocarcinoma; PAAD: Pancreatic adenocarcinoma; BLCA: Bladder Urothelial Carcinoma; CESC: Cervical squamous cell carcinoma; CHOL: Cholangiocarcinoma; ESCA: Esophageal carcinoma; KICH: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; STAD: Stomach adenocarcinoma; THYM: Thyroid carcinoma; THCA: Thyroid carcinoma; BRCA: Breast invasive carcinoma; GBM: Glioblastoma multiforme. N = normal tissue; T = tumor specimen
Article Snippet: IPH5201 ,
Techniques: Gene Expression, RNA Sequencing
Journal: Molecular Cancer
Article Title: CD39/CD73/A2AR pathway and cancer immunotherapy
doi: 10.1186/s12943-023-01733-x
Figure Lengend Snippet: Investigation of monoclonal antibodies or small molecule inhibitors targeting the CD39/CD73/A2AR pathway in clinical trials. ( https://clinicaltrials.gov/ )
Article Snippet: IPH5201 ,
Techniques: Bioprocessing, Clinical Proteomics
Journal: Molecular Cancer
Article Title: CD39/CD73/A2AR pathway and cancer immunotherapy
doi: 10.1186/s12943-023-01733-x
Figure Lengend Snippet: Combinations of CD39/CD73/A2AR inhibitors and other cancer therapies under investigation in clinical trials ( https://clinicaltrials.gov/ )
Article Snippet: IPH5201 ,
Techniques: Clinical Proteomics
Journal: Molecular Cancer
Article Title: CD39/CD73/A2AR pathway and cancer immunotherapy
doi: 10.1186/s12943-023-01733-x
Figure Lengend Snippet: Biomarkers related to the CD39/CD73/A2AR pathway in cancer
Article Snippet: IPH5201 ,
Techniques: Gene Expression, Expressing, Activity Assay, Diagnostic Assay, Biomarker Discovery, Blocking Assay